Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical imiquimod for refractory idiopathic granulomatous mastitis
IRCT20100706004329N11Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod in Granulomatous lobular mastitis (GLM), sponsored by Tehran University of Medical Sciences. Primary endpoints: Erythema size, Number of fistulas and 1 more. Started Sep 2021; status: completed.
02
Drugs
imiquimod
03
Conditions
Granulomatous lobular mastitis (GLM)
Beyond the preview
Go deeper on IRCT20100706004329N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100706004329N11.